Pharmaceutical R&D, production, and sales comprise Livzon Pharmaceutical Group as a comprehensive enterprise headquartered in Jinwan District with a registered capital of 953 million yuan ($135 million).

Established in January 1985, the enterprise has unparalleled advantages with three national and four provincial R&D platforms. All 31 production lines of its four pharmaceutical preparation production subsidiaries have earned Good Manufacturing Practice (GMP) certification.

Headquarters of Livzon Pharmaceutical Group in Jinwan District [Photo courtesy WeChat account: zhuhaifabu]

Moreover, 28 product varieties of its four active pharmaceutical ingredient (API) companies have received GMP certification, and 11 others have acquired veterinary medicine GMP certification. Fifteen API varieties have passed on-site inspections and obtained 20 certificates issued by international certification bodies.

Livzon has developed more than 400 types of API, chemical, biological, and biochemical drugs, proprietary Chinese medicines, and diagnostic reagents, more than 90 of which involving digestive, cardio-cerebrovascular, reproductive endocrinology, psychotropic/neurological, anti-infectious, and anti-tumor compounds are in production and on the market.

Its products have not only been sold to more than 400 domestic cities and are also popular abroad. Market shares of acarbose, tobramycin sulfate, Selamectin, Mibemycin Oxime, Moxidectin, Kara series products, Mevastatin, Lovastatin, and mycophenolic acid rank top in the world.

The company was listed on China's A- and B-share markets in 1993 and completed the conversion from B- to H-shares in Hong Kong in 2014. It is one of the few domestic listed pharmaceutical companies with both A- and H-shares in the capital market.

In 2019, the group's enterprise recorded total assets valued at 17.98 billion yuan ($2.54 billion), annual operating revenue of 9.39 billion yuan ($1.33 billion), and net profit of 1.46 billion yuan ($206 million). R&D expenditure reached 827 million yuan ($117 million).